Abstract
In adjuvant therapy cost-benefit considerations must weigh not only short term toxicities and psychological distress against gain in survival time, but also subacute and late toxicities. In addition, the financial cost per years of life gained by various medical interventions must also be considered to an increasing degree.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Brunner, K.W. (1993). Long-Term Toxicity and Economic Aspects: Critical Review. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-84745-5_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84747-9
Online ISBN: 978-3-642-84745-5
eBook Packages: Springer Book Archive